Say what the evidence supports
Here is the evidence. Here is what it supports. Here is what it does not. We do not say AI found an opportunity.
Company
DAO of Drugs builds TheraSignal.
DAO of Drugs builds TheraSignal to help biopharma teams interpret evidence and make informed therapeutic decisions. The work is whether a specific drug in a specific disease is worth serious attention now — and where that drug has actually been studied.
Why we exist
Biopharma already has the data.
The hard part is deciding what that evidence actually supports: whether it applies, whether it still matters, what has to be beaten, and how wide the disease can honestly be.
How we work
Keep judgment reviewed
People hold the scientific and development line where software is not enough. Past calls do not quietly become a ranking engine.
Your materials stay yours
Confidential customer data does not train models or change the product for anyone else. Conclusions stay bounded to the question you asked.
Leadership
Manish Vipani
Founder and CEO
Built healthcare and enterprise platforms at Kaiser Permanente and Wells Fargo. Founder and CEO of DAO of Drugs, building TheraSignal to help teams decide whether a specific drug in a specific disease is worth serious attention now.
Monica Wynn
Vice President, Commercial Strategy
Twenty years translating science into commercial and development strategy across biotech, pharma, CROs, and clinical laboratories. Leads how TheraSignal reaches BD, portfolio, and partner teams.
Amelia Cline
Chief Development Strategy Officer
Fifteen-plus years taking programs from early research through late-stage development across oncology, immunology, metabolic disease, and neurology. Holds the development and regulatory boundary of what the evidence can actually support.
Nancy Wilcox
Head of Clinical Operations
Over 25 years in clinical operations and global trial management. Completed 6 NDA packages across AIDS, anti-infective, topical dermatology/oncology (AK), and pain, including an NDA completed in 36 months and a later NDA completed in 10 months. Head of clinical operations at Pharma-C, Abbott, and Celgene, with trials in India, North America, and Europe.